Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 16 May, 2014 and appeared in  MedicationGastroenterologyIssue 729

Potential Treatment for Symptoms of Diabetic Gastroparesis

In a phase 2 trial, patients with diabetic gastroparesis displayed increased gastric emptying and improvement in vomiting after treatment with relamorelin-131.... 

Advertisement

In a phase 2 trial, researchers randomly assigned 204 patients with diabetic gastroparesis (DG) (mean age, 55.1 years; 32.3% men) into a double blind, placebo-controlled study for 28 days. Patients were enlisted to take two daily injections of relamorelin-131 10 mcg (RM-131; Rhythm) before an evening meal (n=67), RM-131 10 mcg before breakfast and an evening meal (n=68) or placebo (n=69). Patients' daily symptoms were recorded on a 0-10 scale, and a gastric emptying breath test (GEBT) was performed at baseline and on day 28.

Patients who received RM-131 before breakfast and evening meals showed accelerated GE (P<.03), the study's primary endpoint, and an improvement in vomiting (P=.033), compared with placebo patients. Results for patients who took RM-131 only before evening meals were not presented.

Post-hoc analysis of 119 patients with baseline vomiting revealed that RM-131 had a positive effect on GE, and overall weekly vomiting was reduced by 63%. This subgroup also exhibited improvements in nausea, bloating, early satiety and abdominal pain, compared with the placebo arm (P<.043). Few adverse events occurred, according to the study.

Anthony Lembo, MD, gastroenterologist at Beth Israel Deaconess Medical Center, Boston, stated that, "In summary, RM-131 10 mcg twice daily showed more efficacy than once daily." "In post-hoc analysis in the subgroup of patients, RM-131 10 mcg twice daily is effective in all endpoints. There were no safety concerns seen in the studies."

Practice Pearls:
  • Selective ghrelin pentapeptide relamorelin-131, showed positive results in treating gastroparesis
  • The results of this study are preliminary and no conclusions should be made until it has been reviewed and published.

Presented at: Digestive Disease Week 2014; May 3-6; Chicago. Lembo A. #929a. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  MedicationGastroenterologyIssue 729

Past five issues: Issue 739 | GLP-1 Special Editions July 2014 | Diabetes Clinical Mastery Series Issue 198 | Issue 738 | Diabetes Clinical Mastery Series Issue 197 |

2014 Most Popular Articles:

U.S. FDA Approves Inhaled Insulin: What Medical Professionals Need to Know
Posted July 04, 2014
Newly Updated: Comprehensive List of Insulins
Posted June 30, 2014
Can Insulin Treatment Do More Harm Than Good for Older Type 2's?
Posted July 04, 2014
ADA: Lantus Losing Its Superiority to Newer Treatments
Posted June 20, 2014
ADA: Another Inhaled Insulin Treatment for Type 1 and 2 Diabetes May Be Coming Soon
Posted June 26, 2014
Too Much Medication for Elderly Diabetes Patients?
Posted July 11, 2014
Which Is Better for BG Control: Aerobic or Anaerobic Exercise?
Posted July 11, 2014
Association between Diabetic Foot Ulceration and Premature Death
Posted July 04, 2014
ADA: The Bionic Pancreas
Posted June 26, 2014
ADA: New HbA1c Target of 7.5% for Type 1 Children and Older Adults
Posted June 20, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
Cast Your Vote
Do you offer group education sessions in your practice?
CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control